Loading...
•
Sep 30, 2024
Intra-Cellular Q3 2024 Earnings Report
Intra-Cellular Therapies reported strong growth in Caplyta sales and is preparing for a potential launch of Caplyta for adjunctive treatment of MDD in 2025.
Key Takeaways
Intra-Cellular Therapies announced its Q3 2024 financial results, highlighted by a 39% increase in Caplyta net product sales, reaching $175.2 million compared to the same period in 2023. The company is also on track to submit its sNDA for adjunctive treatment of MDD and raised its full year 2024 net product sales guidance for Caplyta to $665 to $685 million.
Caplyta Q3 2024 net product sales were $175.2 million, a 39% increase compared to Q3 2023.
Total revenues for Q3 2024 were $175.4 million, compared to $126.2 million for the same period in 2023.
The company is preparing to submit its sNDA for adjunctive treatment of MDD in Q4 2024.
Caplyta full year 2024 net product sales guidance range raised to $665 to $685 million.
Intra-Cellular
Intra-Cellular
Forward Guidance
Intra-Cellular Therapies raised its Caplyta full year 2024 net product sales guidance range and narrowed its SG&A and R&D expense guidance ranges.
Positive Outlook
- Caplyta full year 2024 net product sales guidance range raised to $665 to $685 million.
- SG&A expense guidance narrowed to $490 to $510 million.
- R&D expense guidance narrowed to $220 to $230 million.
- sNDA submission for adjunctive treatment of MDD anticipated in Q4 2024.
- Commercial team actively preparing for a potential launch in 2025.